Baxter Cuts Dividend by 41% Ahead of Kidney-Care Unit Sale

Dow Jones11-12
 

By Colin Kellaher

 

Baxter International has reduced its dividend by 41% ahead of the medical-products maker's planned $3.8 billion sale of its kidney-care segment to Carlyle Group.

Baxter late Monday said its board declared a quarterly dividend of 17 cents, down from the 29-cent rate the Deerfield, Ill., company had been paying.

The new payout, equal to 68 cents a year, represents an annual yield just under 2% based on Monday's closing price of $34.22, down from 3.39% previously.

Baxter early last year said it created a standalone kidney-care company as part of a broader realignment, and in August signed a deal to sell the unit to Carlyle, with a closing expected in late 2024 or early 2025.

Baxter, which previously said it would use the roughly $3 billion in after-tax cash proceeds from the deal to pare its debt load, said the new dividend rate targets a payout ratio of about 25% of adjusted earnings, which the company said is in line with its peers.

Baxter said the reduced dividend is payable Jan. 2 to shareholders of record Nov. 29.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 12, 2024 06:36 ET (11:36 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment